78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Pipeline Review, H1 2016

78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Pipeline Review, H1 2016
Published Jun 30, 2016
51 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Pipeline Review, H1 2016, provides in depth analysis on 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) targeted pipeline therapeutics.

The report provides comprehensive information on the 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5)
- The report reviews 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) targeted therapeutics and

  
Source:
Document ID
GMDHC0241TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Overview61
Therapeutics Development74
  78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Products under Development by Stage of Development71
  78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Products under Development by Therapy Area81
  78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Products under Development by Indication92
78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Products under Development by Companies132
78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Therapeutics Assessment157
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action162
  Assessment by Route of Administration182
  Assessment by Molecule Type202
78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Companies Involved in Therapeutics Development223
  Arno Therapeutics, Inc.221
  Intezyne, Inc231
  Nuevolution AB241
78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Drug Profiles2510
  AR-12 Drug Profile253
  IT-139 Drug Profile282
  NEO-100 Drug Profile302
  Rasolvir Drug Profile321
  Recombinant Peptide to Target TPI-1 and GRP-78 for Oncology Drug Profile331
  Small Molecule to Inhibit GRP78 for Oncology Drug Profile341
78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Dormant Projects351
78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Featured News &Press Releases3614
  May 13, 2016: NeOnc Technologies Announces Initiation of Phase 1/2a Clinical Trial of NEO100 in Recurrent Glioblastoma Multiforme (GBM)361
  Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis362
  Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains381
  Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference391
  Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs401
  Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition411
  Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015421
  May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research431
  May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12441
  Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases451
  May 24, 2012: Niiki Pharma To Present Final Phase I Clinical Data On Anti-Cancer Agent, NKP-1339 At Annual Meeting Of ASCO 2012451
  Feb 15, 2012: Niiki Pharma's New Compound Found To Be Promising Against Cancer461
  Feb 01, 2012: Niiki Pharma Forms Scientific Advisory Board, To Focus On Anti-cancer Compound NKP-1339461
  Jan 17, 2012: Niiki Pharma Completes Phase I Dose Escalation For First-In-Man Anti-Cancer Agent, NKP-1339471
  Nov 15, 2011: Niiki Pharma Reports On Synergistic Activity Of New Anti-Cancer Agent NKP-1339 With Other Anti-Cancer Agents482
Appendix502
  Methodology501
  Coverage501
  Secondary Research501
  Primary Research501
  Expert Panel Validation501
  Contact Us501
  Disclaimer511

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/78-kda-Glucose-Regulated-Protein-Endoplasmic-Reticulum-Lumenal-Ca-2-Binding-Protein-Grp78-or-GRP78-or-Heat-Shock-70-kDa-Protein-5-or-Immunoglobulin-Heavy-Chain-Binding-Protein-or-BiP-or-HSPA5-Pipeline-Review-H1-2016-2088-16118>
  
APA:
Global Markets Direct - Market Research. (2016). 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/78-kda-Glucose-Regulated-Protein-Endoplasmic-Reticulum-Lumenal-Ca-2-Binding-Protein-Grp78-or-GRP78-or-Heat-Shock-70-kDa-Protein-5-or-Immunoglobulin-Heavy-Chain-Binding-Protein-or-BiP-or-HSPA5-Pipeline-Review-H1-2016-2088-16118>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.